Xuebijing exerts protective effects on lung permeability leakage and lung injury by upregulating Toll-interacting protein expression in rats with sepsis

International Journal of Molecular Medicine

Volumn 34, Issue 6, 2014, Pages 1492-1504

  Liu, Ming Wei ^a   Wang, Yun Hui ^a   Qian, Chuan Yun ^a   Li, Hui ^a  

^a KUNMING MEDICAL UNIVERSITY   (China)

Author keywords

Interleukin 1 receptor associated kinase 1; Lung permeability; Oxidative stress; Rats; Sepsis; Toll interacting protein; Xuebijing

Indexed keywords

ALBUMIN; ANTIINFLAMMATORY AGENT; BINDING PROTEIN; CHINESE DRUG; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; MYELOPEROXIDASE; SUPEROXIDE DISMUTASE; TOLL INTERACTING PROTEIN; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG; XUEBIJING; CYTOKINE; HERBACEOUS AGENT; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE; IRAK1 PROTEIN, RAT; LIGATIN; MEMBRANE PROTEIN; SIGNAL PEPTIDE; TLR4 PROTEIN, RAT; TOLLIP PROTEIN, RAT; TRANSCRIPTION FACTOR RELA; VON WILLEBRAND FACTOR;

ACUTE LUNG INJURY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTERIAL GAS; ARTICLE; BLOOD VESSEL PERMEABILITY; CARTHAMI; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MECHANISM; DRY WEIGHT; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL LIGATION; HISTOPATHOLOGY; INFLAMMATORY INFILTRATE; LIGUSTICUM CHUANXIONG; LUNG LAVAGE; LUNG WEIGHT; MALE; MEDICINAL PLANT; MOUSE; NEUTROPHIL COUNT; NONHUMAN; PAEONIA; PNEUMONIA; PROTEIN EXPRESSION; PUNCTURE; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SALVIA MILTIORRHIZA; SEPSIS; TIBETAN MEDICINE; UPREGULATION; WESTERN BLOTTING; ADVERSE EFFECTS; ANIMAL; BLOOD; CAPILLARY PERMEABILITY; CECUM; DRUG EFFECTS; GENE EXPRESSION; GENETICS; LUNG; LUNG INJURY; METABOLISM; PHYTOTHERAPY; SPRAGUE DAWLEY RAT; SURGERY; VASCULARIZATION;

ANIMALS; BLOTTING, WESTERN; CAPILLARY PERMEABILITY; CECUM; CYTOKINES; DRUGS, CHINESE HERBAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG; LUNG INJURY; MALE; MEMBRANE PROTEINS; PHYTOTHERAPY; PUNCTURES; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEPSIS; TNF RECEPTOR-ASSOCIATED FACTOR 6; TOLL-LIKE RECEPTOR 4; TRANSCRIPTION FACTOR RELA; UP-REGULATION; VON WILLEBRAND FACTOR;

EID: 84908080179     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2014.1943     Document Type: Article

References (55)

1. Ware LB and Matthay MA: The acute respiratory distress syndrome. N Engl J Med 342: 1334-1349, 2000.
2. Rubenfeld GD, Caldwell E, Peabody E., Weaver J, Martin DP, Neff M, Stern EJ and Hudson LD: Incidence and outcomes of acute lung injury. N Engl J Med 353: 1685-1693, 2005.
3. Berthiaume Y, Folkesson HG and Matthay MA: Lung edema clearance: 20 years of progress. invited review: alveolar edema fluid clearance in the injured lung. J Appl Physiol 93: 2207-2213, 2002.
4. Burns K, Clatworthy J, Martin L., Martinon F, Plumpton C, Maschera B., Lewis A, Ray K, Tschopp J and Volpe F: Tollip, a new component of the IL-1RI pathway, links IRAK to the IL-1 receptor. Nat Cell Biol 2: 346-351, 2000.
5. Yamakami M and Yokosawa H: Tom1 (target of Myb 1) is a novel negative regulator of interleukin-1- and tumor necrosis factor-induced signaling pathways. Biol Pharm Bull 27: 564-566, 2004.
6. Yamakami M, Yoshimori T and Yokosawa H: Tom1, a VHS domaincontaining protein, interacts with Tollip, ubiquitin, and clathrin. J Biol Chem 278: 52865-52872, 2003.
7. Katoh Y, Shiba Y, Mitsuhashi H., Yanagida Y, Takatsu H and Nakayama K: Tollip and Tom1 form a complex and recruit ubiquitin conjugated proteins onto early endosomes. J Biol Chem 279: 24435-24443, 2004.
8. Brissoni B, Agostini L, Kropf M., Martinon F, Swoboda V1, et al: Intracellular trafficking of interleukin-1 receptor I requires Tollip. Curr Biol 16: 2265-2270, 2006.
9. Zhang G and Ghosh S: Negative regulation of Toll-like receptor mediated signaling by Tollip. J Biol Chem 277: 7059-7065, 2002.
10. Capelluto DG: Tollip: a multitasking protein in innate immunity and protein trafficking. Microbes Infect 14: 140-147, 2012.
11. Sugi Y, Takahashi K, Nakano K., Hosono A and Kaminogawa S: Transcription of the Tollip gene is elevated in intestinal epithelial cells through impaired O-GlcNAcylation-dependent nuclear translocation of the negative regulator Elf-1. Biochem Biophys Res Commun 412: 704-709, 2011.
12. Sun ML, Ma DH, Liu M, Yu Y.X., Cao DB, Ma C, Wang X and Liu XL: Successful treatment of paraquat poisoning by Xuebijing, an injection concocted from multiple Chinese medicinal herbs: a case report. J Altern Complement Med 15: 1375-1378, 2009.
13. Celik S, Erdogan S and Tuzcu M: Caffeic acid phenethyl ester (CAPE) exhibits significant potential as an antidiabetic and liver-protective agent in streptozotocin-induced diabetic rats. Pharmacol Res 60: 270-276, 2009.
14. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ: Protein measurement with the folin phenol reagent. J Biol Chem 193: 265-275, 1951.
15. Kakkar P, Das B and Viswanathan PN: A modified spectro-photometric assay of superoxide dismutase. Indian J Biochem Biophys 21: 130-132, 1984.
16. Rokicki W, Zalejska-Fiolka J, Mrukwa-Kominek E, Majewski W and Birkner E: Effect of selected dietary compounds on extracellular superoxide dismutase in the vitreous of chinchillas. Ophthalmic Res 50: 54-58, 2013.
17. von Leitner E.C., Klinke A, Atzler D., Slocum JL, Lund N, Kielstein JT, Maas R, Schmidt-Haupt R, Pekarova M., Hellwinkel O, Tsikas D, D'Alecy LG, Lau D, Willems S., Kubala L, Ehmke H, Meinertz T., Blankenberg S, Schwedhelm E, Gadegbeku CA, Böger RH, Baldus S and Sydow K: Pathogenic cycle between the endogenous nitric oxide synthase inhibitor asymmetrical dimethylarginine and the leukocyte-derived hemoprotein myeloperoxidase. Circulation 124: 2735-2745, 2011.
18. Zhang B, Liu ZY, Li Y.Y., Luo Y., Liu ML, Dong HY, Wang YX, Liu Y, Zhao P.T., Jin FG and Li ZC: Antiinflammatory effects of matrine in LPS-induced acute lung injury in mice. Eur J Pharm Sci 44: 573-579, 2011.
19. Zhang L, Luo N, Liu J., Duan Z, Du G, Cheng J., Lin H and Li Z: Emulsified isoflurane preconditioning protects against liver and lung injury in rat model of hemorrhagic shock. J Surg Res 171: 783-790, 2011.
20. Szapiel SV, Elson NA, Fulmer J.D., Hunninghake GW and Crystal RG: Bleomycin-induced interstitial pulmonary disease in the nude, athymic mouse. Am Rev Respir Dis 120: 893-899, 1979.
21. Risøe P.K., Ryg U, Wang Y.Y., Rutkovskiy A., Smedsrød B, Valen G and Dahle MK: Cecal ligation and puncture sepsis is associated with attenuated expression of adenylyl cyclase 9 and increased miR142-3p. Shock 36: 390-395, 2011.
22. Li HF, Sun MG, Yu YX and Liu XL: Xuebijing alters tumor necrosis factor-alpha, interleukin-1beta and p38 mitogen activated protein kinase content in a rat model of cardiac arrest following cardiopulmonary resuscitation. Neural Regen Res 6: 2573-2576, 2011.
23. Chen Y, Tong HS, Zhang X.Q., Tang LQ, Pan ZG, Liu ZF, Duan PK and Su L: Xuebijing injection alleviates liver injury by inhibiting secretory function of Kupffer cells in heat stroke rats. J Tradit Chin Med 33: 243-249, 2013.
24. Qi F, Liang ZX, She D.Y., Yan GT and Chen LA: A clinical study on the effects and mechanism of xuebijing injection in severe pneumonia patients. J Tradit Chin Med 31: 46-49, 2011.
25. + regulatory T cells in patients with sepsis. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 23: 430-434: 2011 (In Chinese).
26. Sun J, Xue Q, Guo L., Cui L and Wang J: Xuebijing protects against lipopolysaccharide-induced lung injury in rabbits. Exp Lung Res 36: 211-218, 2010.
27. Zhou G, Kamenos G, Pendem S., Wilson JX and Wu F: Ascorbate protects against vascular leakage in cecal ligation and puncture-induced septic peritonitis. Am J Physiol Regul Integr Comp Physiol 302: R409-R416, 2012.
28. Nan YH, Park IS, Hahm KS and Shin SY: Antimicrobial activity, bactericidal mechanism and LPS-neutralizing activity of the cell-penetrating peptide pVEC and its analogs. J Pept Sci 17: 812-817, 2011.
29. Hukkanen RR, Liggitt HD, Murnane RD and Frevert CW: Systemic inflammatory response syndrome in nonhuman primates culminating in multiple organ failure, acute lung injury, and disseminated intravascular coagulation. Toxicol Pathol 37: 799-804, 2009.
30. Moncada-Pazos A., Obaya AJ, Llamazares M, Heljasvaara R., Suárez MF, Colado E., Noël A, Cal S and López-Otín C: ADAMTS-12 metalloprotease is necessary for normal inflammatory response. J Biol Chem 287: 39554-39563, 2012.
31. Ghosh S and Hayden MS: Newregulators of NF-κB in inflammation. Nat Rev Immunol 8: 837-848, 2008.
32. Zhao D, Ding R, Mao Y., Wang L, Zhang Z and Ma X: Heparin rescues sepsis-associated acute lung injury and lethality through the suppression of inflammatory responses. Inflammation 35: 1825-1832, 2012.
33. Ji MH, Zhu XL, Liu F.F., Li GM, Tian M, Wu J, Fan Y.X., Li N and Yang JJ: Alpha 2A-adrenoreceptor blockade improves sepsis-induced acute lung injury accompanied with depressed high mobility group box-1 levels in rats. Cytokine 60: 639-645, 2012.
34. Li X, Zheng Z, Li X and Ma X: Unfractionated heparin inhibits lipopolysaccharide-induced inflammatory response through blocking p38 MAPK and NF-κB activation on endothelial cell. Cytokine 60: 114-121, 2012.
35. Biswas A, Wilmanski J, Forsman H., Hrncir T, Hao L, Tlaskalova-Hogenova H and Kobayashi KS: Negative regulation of Toll-like receptor signaling plays an essential role in homeostasis of the intestine. Eur J Immunol 41: 182-194, 2011.
36. Ostuni R, Zanoni I and Granucci F: Deciphering the complexity of Toll-like receptor signaling. Cell Mol Life Sci 67: 4109-4134, 2010.
37. Liew FY, Xu D, Brint EK and O'Neill LA: Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol 5: 446-458, 2005.
38. Oshima N, Ishihara S, Rumi MAK, Aziz MM, Mishima Y, Kadota C., Moriyama I, Ishimura N, Amano Y and Kinoshita Y: A20 is an early responding negative regulator of Toll-like receptor 5 signalling in intestinal epithelial cells during inflammation. Clin Exp Immunol 159: 185-198, 2010.
39. Wald D, Qin J, Zhao Z., Qian Y, Naramura M, Tian L., Towne J, Sims JE, Stark GR and Li X: SIGIRR, a negative regulator of Toll-like receptor-interleukin 1 receptor signaling. Nat Immunol 4: 920-927, 2003.
40. Kobayashi K, Hernandez LD, Galan J.E., Janeway CA Jr, Medzhitov R and Flavell RA: IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 110: 191-202, 2002.
41. Bulut Y, Faure E, Thomas L., Equils O and Arditi M: Cooperation of toll-like receptor 2 and 6 for cellular activation by soluble tuberculosis factor and Borrelia burgdorferi outer surface protein a lipoprotein: role of tollinteracting protein and IL-1 receptor signaling molecules in toll-like receptor 2 signaling. J Immunol 167: 987-994, 2001.
42. Burns K, Janssens S, Brissoni B., Olivos N, Beyaert R and Tschopp J: Inhibition of interleukin 1 receptor/toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4. J Exp Med 197: 263-268, 2003.
43. Neumann D, Lienenklaus S, Rosati O and Martin MU: IL-1β-induced phosphorylation of PKB/Akt depends on the presence of IRAK-1. Eur J Immunol 32: 3689-3698, 2002.
44. Shimizu K, Taniyama Y, Sanada F., Azuma J, Iwabayashi M, Iekushi K., Rakugi H and Morishita R: Hepatocyte growth factor inhibits lipopolysaccharide-induced oxidative stress via epithelial growth factor receptor degradation. Arterioscler Thromb Vasc Biol 32: 2687-2693, 2012.
45. Bastarache JA, Sebag SC, Clune J.K., Grove BS, Lawson WE, Janz DR, Roberts L.J., Dworski R., Mackman N and Ware LB: Low levels of tissue factor lead to alveolar haemorrhage, potentiating murine acute lung injury and oxidative stress. Thorax 67: 1032-1039, 2012.
46. Bedirli N, Demirtas CY, Akkaya T, Salman B., Alper M, Bedirli A and Pasaoglu H: Volatile anesthetic preconditioning attenuated sepsis induced lung inflammation. J Surg Res 178: e17-e23, 2012.
47. Yageta Y, Ishii Y, Morishima Y., Masuko H, Ano S, Yamadori T., Itoh K, Takeuchi K, Yamamoto M and Hizawa N: Role of Nrf2 in host defense against influenza virus in cigarette smoke-exposed mice. J Virol 85: 4679-4690, 2011.
48. Boutten A, Goven D, Boczkowski J and Bonay M: Oxidative stress targets in pulmonary emphysema: focus on the Nrf2 pathway. Expert Opin Ther Targets 14: 329-346, 2010.
49. Cho HY, Imani F, Miller-DeGraff L, Walters D., Melendi GA, Yamamoto M, Polack FP and Kleeberger SR: Antiviral activity of Nrf2 in a murine model of respiratory syncytial virus disease. Am J Respir Crit Care Med 179: 138-150, 2009.
50. Jeong SJ, Han SH, Kim C.O., Choi JY and Kim JM: Anti-vascular endothelial growth factor antibody attenuates inflammation and decreases mortality in an experimental model of severe sepsis. Crit Care 17: R97-R98, 2013.
51. Qiu Y, Ferguson J, Oltean S., Neal CR, Kaura A, Bevan H, Wood E., Sage LM, Lanati S, Nowak DG, Salmon A.H., Bates D and Harper SJ: Overexpression of VEGF165b in podocytes reduces glomerular permeability. J Am Soc Nephrol 21: 1498-1509, 2010.
52. Jezovnik MK and Poredos P: Idiopathic venous thrombosis is related to systemic inflammatory response and to increased levels of circulating markers of endothelial dysfunction. Int Angiol 29: 226-231, 2010.
53. Hack CE and Zeerleder S: The endothelium in sepsis: source of and a target for inflammation. Crit Care Med 29: S21-S27, 2001.
54. Reinhart K, Bayer O, Brunkhorst F and Meisner M: Markers of endothelial damage in organ dysfunction and sepsis. Crit Care Med 30: S302-S312, 2002.
55. Lucas R, Sridhar S, Rick F.G., Gorshkov B., Umapathy NS, Yang G, Oseghale A, Verin A.D., Chakraborty T., Matthay MA, Zemskov EA, White R, Block NL and Schally AV: Agonist of growth hormone-releasing hormone reduces pneumolysin-induced pulmonary permeability edema. Am J Physiol Renal Physiol 303: F1026-F1036, 2012.